High mobility group a proteins as tumor markers.

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Overexpression of High Mobility Group AT-hook (HMGA) proteins was initially linked to malignant transformation in rat thyroid cells nearly 30 years ago.
• Subsequent research has extensively investigated HMGA protein expression across various human cancers.

Purpose of the Study:

• To summarize findings on HMGA protein expression in human neoplasias.
• To highlight the prognostic value of HMGA proteins in specific cancer types and their potential as diagnostic tumor markers.

Main Methods:

• Review and synthesis of existing studies on HMGA protein expression in human cancers.
• Analysis of correlations between HMGA overexpression and clinicopathological features such as chemoresistance, metastasis, and survival.

Main Results:

• HMGA protein overexpression is consistently associated with a highly malignant phenotype in most cancers.
• Elevated HMGA levels indicate a poor prognosis, particularly in breast, lung, and colon carcinomas, suggesting the need for aggressive treatment strategies.
• HMGA2 expression in lung carcinomas frequently correlates with the presence of metastases.
• Deregulated expression of non-coding RNA is often responsible for elevated HMGA protein levels in malignancies.

Conclusions:

• HMGA proteins serve as valuable tumor markers for cancer diagnosis and prognosis.
• Detection of HMGA proteins can inform more aggressive therapeutic approaches for certain cancers.
• Understanding the role of non-coding RNA in HMGA regulation is crucial for cancer research.